Table 2.

Summary of PD effect (E_max) of dabigatran on aPTT prolongation, INR, TT and ECT in the single- and multiple-dose studies

	aPTT Mean, range		INR Mean, range		TT Mean, range		ECT Mean, range
Dabigatran etexilate dose (mg)	Emax	CV%	Emax	CV%	Emax	CV%	Emax	CV%
					1.25		1.19
Single-dose study					1.18–1.39	7.1%	1.14–1.25	4.1
10	1.16	5.5%	1.14	6.8%	2.77	53.9%	1.39	12.8%
	1.10–1.25		1.09–1.29		1.63–5.62		1.21–1.68
30	1.25	9.2%	1.22	4.5%	10.5	19.9%	2.42	14.0%
	1.15–1.46		1.17–1.32		7.94–13.7		1.98–2.94
100	1.58	4.6%	1.30	8.9%	19.3	41.5%	3.28	19.8%
	1.48–1.69		1.11–1.39		13.1–35.1		2.69–4.49
200	1.81	7.3%	1.47	7.6%	56.5	29.1%	5.30	26.1%
	1.67–2.03		1.31–1.63		23.0–64.5		3.65–6.87
400	2.08	12.1%	1.88	13.4%
	1.79–2.41		1.61–2.18		Emax,ss	CV%	Emax,ss	CV%
	Emax,ss	CV%	Emax,ss	CV%	Emax,ss	CV%	Emax,ss	CV%
Multiple-dose study
50	1.46	6.1%	1.31	4.1%	7.81	29.3%	2.16	14.4%
	1.40–1.61		1.23–1.40		4.96–10.3		1.80–2.56
100	1.92	7.0%	1.73	5.5%	13.9	15.9%	3.75	14.9%
	1.80–2.11		1.59–1.92		10.3–17.4		3.05–4.37
200	2.34	8.2%	1.78	9.7%	26.9	7.6%	5.20	9.6%
	2.00–2.57		1.46–2.00		23.6–30.1		4.49–6.27
400	3.12	10.8%	3.49	31.7%	29.1	13.4%	9.49	14.5%
	2.77–3.72		2.34–5.50		24.0–35.9		7.87–11.9